Biopharmaceutical Tubing Market Report 2024

This Biopharmaceutical Tubing industry report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The biopharmaceutical tubing market size has grown rapidly in recent years. It will grow from $3.88 billion in 2023 to $4.32 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth during the historic period can be attributed to an increased demand for minimally invasive procedures, a growing elderly population, a heightened need for ultra-pure and corrosion-resistant systems, and a surge in the demand for diagnostic equipment and drug delivery systems.

The biopharmaceutical tubing market size is expected to see rapid growth in the next few years. It will grow to $6.65 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to increasing biopharmaceutical production, stricter regulatory policies, a rising need for efficient and contamination-free bioprocessing, heightened safety measures, and growing investment in pharmaceutical R&D. Key trends expected during this period include advancements in single-use systems, innovations in tubing materials, development of customized tubing solutions, and improvements in tubing design.

The growing use of personalized medicines is expected to drive the expansion of the biopharmaceutical tubing market. Personalized medicine is an approach that customizes healthcare decisions, practices, interventions, and treatments to match the individual characteristics of each patient. This approach is gaining traction due to advancements in genetic research, which allow for treatment strategies tailored to an individual’s genetic profile, lifestyle, and specific health conditions. Biopharmaceutical tubing plays a crucial role in personalized medicine by ensuring precise, sterile, and reliable fluid transfer, which is essential for delivering customized treatments and therapies. For instance, in 2022, the Personalized Medicine Coalition, a US-based membership organization, reported the approval of 12 new personalized medicines, representing about 34% of all newly approved therapies. This marks a significant increase compared to previous years, highlighting the role of personalized medicines in driving the growth of the biopharmaceutical tubing market.

Key players in the biopharmaceutical tubing market are advancing their product offerings with next-generation solutions, such as bioabsorbable tubing, to enhance performance, sterility, and fluid handling for advanced biopharmaceutical applications. Bioabsorbable tubing is made from materials that gradually break down and are absorbed by the body, eliminating the need for removal after use. For example, in September 2023, Zeus Company Inc., a US-based provider of advanced polymer solutions, introduced the Absorv XSE-oriented tubing, a next-generation bioabsorbable product designed for bioresorbable vascular scaffolds (BRS). This innovation allows medical device manufacturers to explore BRS applications beyond treating coronary artery disease and potentially replace metallic stents in various procedures. The new tubing offers improved wall thickness and sizing uniformity, enhancing efficiency during laser cutting processes and resulting in more usable scaffolds.

In February 2024, EQT Private Equity, a Sweden-based investment management firm, acquired Zeus Company Inc. for $3.4 billion. This acquisition aims to support Zeus's growth by investing in additional production capacity, research and development, and operational excellence, particularly in medical tubing technology. Zeus Company Inc. is a US-based manufacturer known for precision polymer extrusions and custom tubing.

Major companies operating in the biopharmaceutical tubing market are Compagnie de Saint-Gobain S.A., Thermo Fisher Scientific Inc., Merck KGaA, GE HealthCare Technologies Inc., Parker Hannifin Corporation, DuPont de Nemours Inc., Freudenberg Group, Medline Industries LP, Avantor Inc., Alfa Laval AB, REHAU Group, W. L. Gore & Associates Inc., Sartorius AG, Elkem ASA, Trelleborg AB, Bio-Rad Laboratories Inc., Tekni-Plex Inc., Pall Corporation, Zeus Company Inc., Watson-Marlow Ltd., Raumedic AG, Qosina, Optinova AB, ESI Ultrapure.

North America was the largest region in the biopharmaceutical tubing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical tubing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biopharmaceutical tubing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biopharmaceutical tubing refers to specialized tubing used in the production and handling of biopharmaceutical products. It is engineered to meet rigorous standards for sterility, biocompatibility, and precision to ensure the safe and effective handling of sensitive materials throughout both manufacturing and administration processes.

The main products in the biopharmaceutical tubing market include silicone tubing, polyvinyl chloride (PVC) tubing, polyolefin tubing, and thermoplastic elastomer tubing. Silicone biopharmaceutical tubing is known for its flexibility and high purity, made from silicone rubber and specifically designed for use in the biopharmaceutical industry. Manufacturing processes for these tubes include extrusion and vulcanization, with applications spanning pharmaceuticals, medical devices, research and development, and other areas.

The biopharmaceutical tubing market research report is one of a series of new reports that provides biopharmaceutical tubing market statistics, including the biopharmaceutical tubing industry global market size, regional shares, competitors with biopharmaceutical tubing market share, detailed biopharmaceutical tubing market segments, market trends, and opportunities, and any further data you may need to thrive in the biopharmaceutical tubing industry. These biopharmaceutical tubing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biopharmaceutical tubing market consists of sales of polytetrafluoroethylene (PTFE) tubing, ethylene-vinyl acetate (EVA) tubing, and rubber tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.